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Purpose: To investigate changes in nocturia and predictive factors for improvement 
after photoselective vaporization of the prostate (PVP) for patients with benign pro-
static hyperplasia (BPH).
Materials and Methods: A total of 103 patients who complained of nocturia of ≥2 times 
per night on baseline frequency-volume chart (FVC) and who underwent PVP were in-
cluded in this retrospective study. All patients underwent a preoperative evaluation 
for BPH including multichannel video urodynamics. The efficacy of the PVP was eval-
uated at 1, 3, 6, and 12 months postoperatively by use of the International Prostate 
Symptom Score (IPSS) and FVC. Subjective and objective improvement of nocturia 
were defined as a reduction of ≥50% in nocturnal frequency compared with baseline 
on the IPSS and FVC, respectively.    
Results: As shown by the IPSS and FVC, nocturia was significantly reduced starting 
from 1 month after PVP. The percentage of patients with improvement in nocturia was 
20.0%, 20.7%, 36.2%, and 27.9% on the IPSS, and 30.1%, 48.6%, 52.2%, and 54.5% on 
the FVC at 1, 3, 6, and 12 months after PVP, respectively. None of the baseline parame-
ters, including the presence or absence of nocturnal polyuria (NPU), reduced nocturnal 
bladder capacity (NBC), and detrusor overactivity (DO), were associated with improve-
ment of nocturia.
Conclusions: Nocturnal frequency was significantly reduced from the early post-
operative period after PVP. Improvement in nocturia after PVP was not affected by 
baseline nocturnal frequency, the presence or absence of preoperative NPU, or reduced 
NBC or DO on baseline urodynamics.
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INTRODUCTION
Nocturia, a common cause of interrupted sleep in the gen-
eral adult population, is defined as waking at night one or 
more times to void [1]. Nocturia has adverse effects on qual-
ity of life (QoL), sleep patterns, daytime sleepiness, and 
even mortality associated with falls [2,3]. Nocturia is one 
of the major problems in older men with lower urinary tract 
symptoms (LUTS) suggestive of benign prostatic ob-
struction [4]. Benign prostatic hyperplasia (BPH) can 
cause bladder outlet obstruction and induce secondary de-
trusor overactivity (DO) and reduction of functional blad-
der capacity, which may result in storage symptoms includ-
ing nocturia [5]. Two or more episodes of nocturia were ob-
served for more than 60% of patients with BPH in several 
studies [6,7]. Also, several other risk factors for nocturia 
have been reported, including nocturnal polyuria (NPU) 
and reduced nocturnal bladder capacity (NBC), which are 
generally known as the causal mechanisms of nocturia [5].
Several studies showed a reduction of 0.8 to 1.6 episodes 
of nocturia after surgical treatment such as transurethral 
resection of the prostate (TURP) in patients with BPH 
[5,8,9]. Although TURP has been the gold standard treat-
ment of BPH, its complications, such as bleeding, transure-Korean J Urol 2010;51:531-536
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TABLE 1. Preoperative characteristics and perioperative data
Preoperative characteristics
　Mean±standard deviation or No. of patients (%)
　Demographic variables
　　Age (years) 68.9±6.3
　　PSA (ng/ml)   3.0±3.7
　　Prostate volume (ml)   50.6±23.5
　　Transition zone volume (ml)   26.0±19.7
　Uroflowmetry with PVR
　　Qmax (ml/s) 10.2±6.0
　　PVR (ml)   67.5±68.2
　IPSS
　　Nocturia   3.0±1.0
　　Storage symptom   8.5±3.1
　　Total IPSS 20.9±6.9
　　QoL index   4.4±1.1
　FVC
　　Nocturia   2.5±0.8
　　NPI   0.40±0.10
　　NI   2.2±0.6
　　NBCI   0.8±0.8
　　NPI＞0.33  77/103 (74.8%)
　　NBCI≥1  63/103 (61.2%)
　Urodynamics
　　BOO  34/103 (33.0%)
　　DO  33/103 (32.0%)
　　MCC (ml)   368±102
Perioperative data
　Operative time (min)   53.0±25.9
　Laser energy applied (kJ)   152.1±114.9
　Catheter time (hr)   21.1±10.2
PSA: prostate-specific antigen, PVR: post-void residual urine vol-
ume, Qmax: maximum flow rate, IPSS: International Prostate 
Symptom Score, QoL: quality of life, FVC: frequency-volume 
chart, NPI: nocturnal polyuria index, NI: nocturia index, NBCI: 
nocturnal bladder capacity index, BOO: bladder outlet ob-
struction, DO: detrusor overactivity, MCC: maximum cysto-
metric capacity
thral resection (TUR) syndrome, incontinence, and erectile 
dysfunction, are significant problems. Recently, photo-
selective vaporization of the prostate (PVP) has shown clin-
ical outcomes consistent with TURP but with improved 
morbidity in short- and long-term studies [10-13]. However, 
no research has been dedicated specifically to the effect of 
PVP for BPH on the reduction of nocturia or factors pre-
dictive of improvement in nocturia after PVP. In the pres-
ent study, we investigated changes in nocturia and pre-
dictive factors for improvement after PVP in patients with 
BPH.  
MATERIALS AND METHODS
1. Study design 
This study was approved by the Institutional Review Board 
at the Seoul National University Hospital. Between 
January 2006 and April 2008, a total of 190 patients under-
went PVP for BPH refractory to alpha-blocker medication. 
Among the patients, 103 patients who complained of 2 or 
more episodes of nocturia on a baseline frequency-volume 
chart (FVC) were included in this retrospective study. The 
exclusion criteria were as follows: previous prostate sur-
gery, urethral stricture, prostate malignancy, and neuro-
genic bladder disease.
We used the 80 W potassium-titanyl-phosphate (KTP) 
laser for the PVP. The PVP was performed by a single sur-
geon (J.S.P) in a routine manner as reported previously 
[14]. All patients underwent a preoperative evaluation 
with transrectal ultrasound (TRUS) and multichannel vid-
eo urodynamics (MMS UD-2000, Medical Measurement 
System, Ennschede, The Netherlands) in addition to a gen-
eral standard evaluation for LUTS/BPH including a his-
tory, physical examination including digital rectal exami-
nation (DRE), International Prostate Symptom Score 
(IPSS), 3-day FVC, urinalysis, serum prostate-specific an-
tigen (PSA), and TRUS. Patients with PSA levels exceeding 
4.0 or DRE abnormalities underwent prostate biopsy and 
patients with prostate cancer were excluded from our 
study. Intraoperatively, we measured the operative time, 
lasing time, total laser energy used, and complications 
such as bleeding, injury of the ureteral orifice, or perfo-
ration of the prostatic capsule.
Changes in nocturia after PVP were assessed at 1, 3, 6, 
and 12 months postoperatively by use of the IPSS and 3-day 
FVC. Subjective and objective improvement in nocturia 
were defined as a reduction of ≥50% in episodes of nocturia 
compared with baseline on the IPSS and FVC, respectively. 
We defined the nocturia index (NI), the nocturnal polyuria 
index (NPI), and the nocturnal bladder capacity index 
(NBCI) as follows. 1) NI was the nocturnal urine volume 
(NUV) divided by the maximum voided volume. An NI＞1 
indicated that nocturnal urine production was greater 
than functional bladder capacity. 2) NPI was the NUV div-
ided by the 24-h urine volume. An NPI＞33% implied noc-
turnal polyuria as opposed to diurnal polyuria. 3) The 
NBCI was the difference between the actual number of noc-
turnal voids (ANV) and the predicted number of nocturnal 
voids (PNV), where the PNV was the NI minus 1 [15]. 
Diminished nocturnal bladder capacity was defined as a 
NBCI≥1. From the urodynamic parameters, the bladder 
outlet obstruction index (BOOI) was defined as follows: de-
trusor pressure at maximum flow rate (PdetQmax) - 
2Qmax [16]. BOO was defined as a BOOI greater than 40. 
DO was defined as a urodynamic finding characterized by 
involuntary detrusor contractions during the filling phase, 
either spontaneous or provoked [17]. All definitions corre-
sponded to recommendations of the International Contin- 
ence Society (ICS) [17].
2. Data analysis
All variables are reported as the mean±standard deviation 
or numbers of patients with the percentages in parentheses. 
The variables were evaluated for statistically significant 
differences between the baseline measures and the meas-
ures obtained after PVP by use of the paired t-test. A logistic Korean J Urol 2010;51:531-536
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TABLE 3. Baseline values and changes in PVP outcome parameters according to the IPSS and FVC (patients who did not take 
medication postoperatively)
Baseline 1 month 3 months 6 months 12 months
No. of patients at follow-up 84 83   68 62 54
Mean±standard variation or percentage of patients
IPSS
　Nocturia 3.0±0.9  2.5±1.3
a     2.0±0.9
a 2.0±0.9
a 2.2±1.0
a
　Storage symptom 8.6±3.0  7.5±3.6
a     5.9±2.7
a 4.6±2.5
a 4.9±3.1
a
　QoL index 4.4±1.1  2.7±1.3
a     2.4±1.9
a 2.1±1.4
a 2.1±1.4
a
FVC
　Nocturia 2.5±0.7  1.9±0.9
a     1.8±0.8
a 1.6±0.8
a 1.6±0.8
a
　FBC 330±120 328±110 330±95 352±120
a 355±118
a
　NBCI 0.83±0.80  0.52±0.60
a     0.41±0.69
a 0.35±0.48
a 0.36±0.50
a
　NBCI≥1 60.7 50.6   38.2 38.7 37.0
PVP: photoselective vaporization of the prostate, IPSS: International Prostate Symptom Score, FVC: frequency-volume chart, QoL:
quality of life, FBC: functional bladder capacity, NBCI: nocturnal bladder capacity index, 
ap＜0.05: comparison between the baseline
parameters and parameters obtained after PVP by use of the paired t-test
TABLE 2. Baseline values and changes in PVP outcome parameters according to the IPSS and FVC (total patients)
Baseline 1 month 3 months 6 months 12 months
No. of patients at follow-up 103 100   82 69 61
Mean±standard variation or percentage of patients
IPSS
　Nocturia 3.0±1.0  2.4±1.2
a     2.1±0.9
a 2.0±0.9
a 2.1±1.0
a
　Storage symptom 8.5±3.1  7.3±3.4
a     5.7±2.7
a 4.5±2.4
a 5.1±3.2
a
　QoL index 4.4±1.1  2.7±1.4
a     2.4±1.9
a 2.0±1.3
a 2.1±1.4
a
FVC
　Nocturia 2.5±0.8  2.0±0.9
a     1.7±0.8
a 1.5±0.7
a 1.5±0.8
a
　FBC 327±124 326±117 324±86 358±123
a 359±123
a
　NBCI 0.83±0.82  0.54±0.65
a     0.41±0.67
a 0.34±0.50
a 0.34±0.54
a
　NBCI≥1 61.2 46.8   37.8 35.8 34.5
PVP: photoselective vaporization of the prostate, IPSS: International Prostate Symptom Score, FVC: frequency-volume chart, QoL:
quality of life, FBC: functional bladder capacity, NBCI: nocturnal bladder capacity index, 
ap＜0.05: comparison between the baseline
parameters and parameters obtained after PVP by use of the paired t-test
regression model and odds ratios (with 95% confidence in-
tervals) were used to identify the factors influencing im-
provement in nocturnal frequency. The reported p-values 
are two-sided, and a p-value of 0.05 was considered statisti-
cally significant. The Statistical Package for the Social 
Sciences (SPSS for Windows, release 13.0, SPSS Inc., 
Chicago, IL, USA) was used for data analysis.
RESULTS
The preoperative characteristics and perioperative data 
are shown in Table 1. The mean age of the patients was 
68.9±6.3 years. Mean prostate volume was 50.6±23.5 ml, 
mean operative time was 50.3±25.9 min, and mean laser 
energy was 152.1±114.9 kJ. The patients complained of a 
mean of 3.0±1.0 episodes of nocturia on the IPSS and re-
corded a mean of 2.5±0.8 episodes on the FVC. On the base-
line FVC, 74.8% of the patients had nocturnal polyuria 
(NPI＞0.33) and 61.2% of the patients had reduced NBC 
(NBCI≥1). According to the baseline urodynamics, BOO 
and DO were diagnosed in 32.7% and 32.0% of the patients, 
respectively. The mean follow-up duration was 13.8±2.8 
months.
Nocturnal frequency on the IPSS and FVC showed a stat-
istically significant reduction starting from 1 month after 
PVP compared with baseline (p＜0.05) (Table 2). At 12 
months postoperatively, nocturnal frequency had de-
creased from a baseline mean of 3.0±1.0 episodes to 2.1±1.0 
episodes according to the IPSS and from 2.5±0.8 episodes 
to 1.5±0.8 episodes according to the FVC. Compared with 
the baseline data, the NBCI also decreased significantly by 
degrees.
Preoperatively, the number of patients who had taken 
an alpha-blocker, anticholinergics, and desmopressin was 
85, 17, and 3, respectively. All patients were instructed to 
stop taking the medicine at the time of operation. Posto- 
peratively, we prescribed an alpha-blocker to 5 patients 
with persistent voiding symptoms, anticholinergics to 11 
patients with urgency or urge incontinence, and desmo-
pressin to 3 patients with persistent nocturia. Excluding Korean J Urol 2010;51:531-536
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TABLE 4. Patients with improvement of nocturia postoperatively
according to the IPSS or FVC
1 month 3 months 6 months 12 months
Patients
by IPSS 20/100 17/82 25/69 17/61
(%) (20.0) (20.7) (36.2) (27.9)
by FVC 29/94 36/74 35/67 30/55
(%) (30.1) (48.6) (52.2) (54.5)
IPSS: International Prostate Symptom Score, FVC: frequency- 
volume chart
TABLE 5. Predictive factors of improvement in nocturia
Variables
OR (95% CI)
Nocturia on IPSS Nocturia on FVC
Age (years) 0.986  0.915 
(0.876-1.110) (0.810-1.033)
BMI (kg/m
2) 1.133 0.967
(0.826-1.554) (0.709-1.320)
Hypertension 1.091 1.033
(0.747-1.595) (0.934-1.142)
Diabetes 1.167 1.017 
(0.853-1.462) (0.874-1.185)
PSA (ng/ml) 1.132  1.029 
(0.973-1.318) (0.879-1.204)
Prostate volume (ml) 1.104  1.001 
(0.985-1.044) (0.976-1.026)
Qmax (ml/s) 0.971  0.981 
(0.849-1.110) (0.893-1.079)
PVR (ml) 0.997  1.001 
(0.986-1.009) (0.992-1.010)
IPSS   
Nocturia 1.396 1.369 
(0.621-3.134) (0.626-2.995)
Urgency 1.383 1.199 
(0.511-3.744) (0.451-3.192)
Voiding symptoms 1.088  1.206 
(0.877-1.349) (0.998-1.458)
Storage symptoms 1.111  1.434 
(0.781-1.580) (0.967-2.127)
Total IPSS 1.064  1.176 
(0.911-1.244) (0.999-1.376)
FVC
ANV 1.386 0.975 
(0.367-5.238) (0.295-3.224)
NPI
≤0.33 1.000 1.000
＞0.33 1.111 0.234 
(0.177-6.990) (0.039-1.416)
NI
≤1.5 1.000 1.000
＞1.5 1.281 1.361 
(0.899-1.962) (0.787-2.110)
NBCI
＜1 1.000 1.000
≥1 1.328 1.569 
(0.831-2.261) (0.720-3.472)
UDS
First sense to void (ml) 1.007  1.005 
(0.993-1.020) (0.994-1.017)
MCC (ml) 1.004  1.002 
(0.993-1.015) (0.994-1.012)
Compliance
Normal 1.000 1.000
Low 1.278 0.786 
(0.112-9.587) (0.095-6.501)
DO
Absence 1.000 1.000
Presence 3.150 0.750 
(0.528-9.803) (0.146-3.841)
the 19 patients who took medicines such as an alpha-block-
er, anticholinergics, and desmopressin postoperatively, 
the outcome parameters of the 84 patients who did not take 
medication were not significantly different from those of 
the total group of patients (Table 3).
Table 4 shows the patients (%) with improvement of noc-
turia when subjective and objective improvement was de-
fined as a reduction of ≥50% in episodes of nocturia com-
pared with baseline on the IPSS and FVC, respectively. The 
patients with subjective improvement of nocturia on the 
IPSS increased from 20.0% at 1 month postoperatively to 
36.2% at 6 months postoperatively, then decreased to 
27.9% at 12 months postoperatively. The patients with ob-
jective improvement of nocturia on the FVC increased con-
tinuously from 30.1% at 1 month postoperatively to 54.5% 
at 12 months postoperatively. At 12 months post-
operatively, 27.9% and 54.5% of the patients reported sub-
jective and objective improvement of nocturia on the IPSS 
and FVC, respectively. Also, the NBCI decreased sig-
nificantly starting from 1 month after PVP compared with 
baseline (p＜0.05) (Table 2).
There were no serious intraoperative complications, 
such as bleeding or TUR syndrome. Delayed bleeding was 
reported in 12 cases out of 103 (11.7%). However, no tran-
surethral coagulation was needed, and delayed bleeding 
was resolved spontaneously. Postoperative complications 
were 1 case of urethral stricture (1.0%), 1 of bladder neck 
contracture (1.0%), 8 of urge incontinence (7.8%), and 30 
of retrograde ejaculation (29.1%). There was no de novo 
erectile dysfunction.
A logistic regression analysis was performed to identify 
the factors influencing improvement in nocturia. However, 
none of the factors, including NPU, reduced NBC, and the 
presence of DO at baseline, were associated with subjective 
or objective improvement in nocturia (Table 5). In addition, 
postoperative parameters, including maximum flow rate 
(Qmax), post-void residual urine, functional bladder ca-
pacity, NBCI, and the presence of de novo urgency, were 
not associated with improvement of nocturia.
DISCUSSION
Nocturia is a major cause of disturbed sleep onset and sleep 
maintenance in the general elderly population [18]. Korean J Urol 2010;51:531-536
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TABLE 5. Continued
Variables
OR (95% CI)
Nocturia on IPSS Nocturia on FVC
BOO
Absence 1.000 1.000
Presence 3.182 1.143 
(0.516-9.639) (0.250-5.224)
PdetQmax (cmH2O) 0.991 0.989
(0.958-1.025) (0.950-1.029)
Postoperative parameters
   Qmax 1.017  1.031 
(0.927-1.116) (0.937-1.133)
   PVR  1.003  0.996 
 (0.992-1.010) (0.986-1.009)
   FBC  1.101  1.203 
 (0.910-1.318) (0.956-1.576)
   NBCI  1.567  1.638 
 (0.789-2.486) (0.799-0.978)
   De novo urgency  2.089  1.649 
 (1.150-3.795) (0.635-4.277)
OR: odds ratio, CI: confidence interval, IPSS: International 
Prostate Symptom Score, FVC: frequency-volume chart, BMI: 
body mass index, PSA: prostate-specific antigen, Qmax: max-
imum flow rate, PVR: post-void residual urine volume, ANV: ac-
tual number of nocturnal voids, NPI: nocturnal polyuria index, NI:
nocturia index, NBCI: nocturnal bladder capacity index, UDS: ur-
odynamics, MCC: maximum cystometric capacity, DO: detrusor 
overactivity, BOO: bladder outlet obstruction, PdetQmax: de-
trusor pressure at maximum flow rate, FBC: functional bladder 
capacity
Nocturia has adverse effects on QoL, sleep patterns, day-
time sleepiness, and even mortality associated with falls. 
Elderly people who need to void three or more times per 
night had a greater mortality rate over a 54-month ob-
servation period than did those voiding less often [2,3]. 
Nocturia of 2 or more times is present in 30% of men aged 
50 to 54 years and in 60% of those aged 70 to 78 years old 
[19]. Two or more episodes of nocturia were observed for 
more than 60% of patients with BPH [6,7]. In this study, 
two or more episodes of nocturia were observed for 54.2% 
(103/190) of patients who underwent PVP due to BPH. 
The causal mechanisms of nocturia fall into four catego-
ries: diurnal polyuria, NPU, reduced NBC, and mixed noc-
turia, which is a combination of NPU and reduced NBC [4]. 
BPH is likely associated with reduced NBC. BOO caused 
by BPH results in detrusor instability, neural degener-
ation, and decreases in bladder compliance, and then noc-
turnal bladder capacity is decreased [20]. In our study, 
27.9% and 54.5% of the patients reported subjective and ob-
jective improvement in nocturia on the IPSS and FVC at 
12 months postoperatively. The reduced episodes of noctu-
ria were 0.9 and 1.0 on the IPSS and FVC, respectively.
A plausible explanation for the improvement in nocturia 
after PVP is thought to be similar to that after TURP. After 
prostatectomy, reinnervation of the bladder and recovery 
of detrusor stability occur as a result of relief from the ob-
struction [21-23]. The relief from obstruction may be asso-
ciated with a reduction of urinary frequency and reversal 
of neural changes [24]. Furthermore, TURP effectively de-
stroys the entire urothelium and submucosal tissue of the 
prostatic urethra and the bladder neck region, as well as 
resecting prostatic tissues [25]. Although side-fire laser is 
not as effective in reducing mechanical obstruction, it is 
probably as effective at destroying the prostatic and blad-
der neck urothelium and suburothelial structures [25]. 
Hence, both laser and TURP may be effective by producing 
a "deafferentation" of the afferent neurons responsible for 
initiating the involuntary detrusor contractions charac-
teristic of DO and causing symptoms of overactive bladder 
[25]. Therefore, the denervation effects of prostatectomy on 
the bladder neck and prostatic urethra, or the relief from 
obstruction by the prostatectomy, may also apply to the im-
provement of nocturia after PVP. Also, there is another ex-
planation for the improvement of nocturia after PVP. The 
decreases in post-void residual urine volume, and sub-
sequently the time for bladder filling increases, which 
leads to a reduction of frequency and nocturia; these fea-
tures might be secondary to the relief from obstruction [9]. 
In the present study, NBC increased significantly start-
ing from the early postoperative period; therefore, the im-
provement in nocturia might be partially attributed to the 
increase in NBC. However, some patients did not respond 
to the treatment and complained of persistent nocturia. In 
clinical practice, nocturia might be a symptom of not only 
LUTS/BPH but also of other associated medical conditions 
such as natriuresis, congestive heart failure, diabetes, and 
peripheral edema. Nocturia is influenced by various fac-
tors other than BPH.
In the present study, the IPSS tended to indicate a higher 
prevalence of nocturia than did the FVC. Consistent with 
the present results, McCormack et al reported poor agree-
ment between the FVC and questionnaire results [26]. In 
addition, patients with subjective improvement of nocturia 
on the IPSS decreased from 36.2% at the 6-month visit to 
27.9% at the 12-month visit after the surgery, although 
those increased by 6 months postoperatively. However, 
this could have been due to the relatively high rate of loss 
to follow-up at 12 months postoperatively, resulting in se-
lection bias. 
The limitations of this study include the following. First, 
because the present study was retrospective, it might be 
limited by a possible selection bias. Second, the degree of 
irritation and effects on the disease-specific QoL were as-
sessed only by the IPSS QoL index. Validated ques-
tionnaires are necessary to evaluate the clinical sig-
nificance of nocturia. Third, our study did not include a 
large cohort and the follow-up period was only short-term. 
Fourth, our study was not randomized or controlled by the 
reference standard, TURP. Accordingly, we could not ex-
clude a placebo effect or bias affecting the results of this 
study. Finally, in the present study, the relatively high 
dropout rate of 40.8% 12 months after the PVP may have Korean J Urol 2010;51:531-536
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inadvertently created a selection bias.
CONCLUSIONS
The results of this study suggest that nocturia can improve 
significantly starting from the early postoperative period 
after PVP for symptomatic BPH. However, we found no fac-
tors influencing improvement in nocturia. The improve-
ment in nocturia after PVP was not affected by baseline 
nocturnal frequency, the presence or absence of pre-
operative NPU, or reduced NBC and DO on baseline 
urodynamics. However, longer follow-up studies with a 
larger cohort are needed to confirm these findings.
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